Рынок терапии полимиозита вырастет до 2036 года на фоне новых биологических препаратов

09-08-2026 08:40 AM CET | Health & Medicine Press release from: Delveinsight Business Research LLP DelveInsight's Polymyositis Market Insights, Epidemiology, and Market Forecast 2036 report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology, as well as Polymyositis market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Get a detailed understanding of the evolving Polymyositis treatment landscape: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Key Facts of the Polymyositis Market Report • The Polymyositis market size was ~USD 120 million across the 7MM in 2025, and is anticipated to grow at a CAGR of ~20% between 2026 and 2036, driven by improved disease recognition, earlier diagnosis, and increasing adoption of targeted biologic therapies. • The Polymyositis companies developing therapies in the treatment landscape include AstraZeneca (in partnership with BMS), Pfizer, Argenx, and others. • In May 2025, Teva Pharmaceuticals, in collaboration with Alvotech, has received FDA approval for SELARSIDTM, a biosimilar to Stelara®. This approval enhances their portfolio in immunomodulatory therapies applicable to polymyositis treatment approaches. • In January 2025, RESTEM announced that the FDA has granted Fast Track designation for its Restem-L program, which utilizes umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the program's recent Orphan Drug Designation for IIM. • Anifrolumab (SAPHNELO) is being evaluated in the Phase III JASMINE trial, with AstraZeneca anticipating data in 2027. • Dazukibart (PF-06823859) from Pfizer has received Orphan Drug Designation and Fast Track Designation from the US FDA, along with PRIME Designation from the EMA. • Efgartigimod (Argenx) is in Phase III development, with a data readout anticipated in Q3 2026 per the company's May 2026 corporate presentation. • Positive Phase III outcomes could establish the first disease-specific biologics for Polymyositis, significantly reshaping the competitive landscape and treatment algorithm. Request a sample PDF to explore comprehensive Polymyositis market forecasts: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Polymyositis Overview Polymyositis is a rare, chronic autoimmune inflammatory muscle disease characterized by progressive, symmetrical weakness of the proximal skeletal muscles, particularly affecting the shoulders, hips, neck, and thighs. It results from immune-mediated muscle fiber injury, primarily driven by T-cell-mediated inflammation, and is classified among the Idiopathic Inflammatory Myopathies (IIMs). The disease may present alongside extra-muscular manifestations such as interstitial lung disease, dysphagia, and cardiac involvement. Polymyositis mimics many other myopathies and is considered a diagnosis of exclusion. It most commonly affects adults between ages 50 and 70, and is roughly twice as common in women as in men approximately 75% of US cases in 2025 belonged to female patients. The disease is rare in childhood and typically presents after the second decade of life. Diagnosis relies on a combination of clinical assessment, elevated serum muscle enzymes, myositis-specific autoantibody testing, MRI, electromyography, and muscle biopsy the diagnostic gold standard, which typically reveals CD8-positive T-lymphocyte infiltration of non-necrotic muscle fibers. The 2017 EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies are widely used to support diagnosis. Explore how emerging targeted biologics are transforming the future of the Polymyositis market: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Polymyositis Therapies and Key Companies Key Polymyositis Companies Include: • AstraZeneca • Pfizer • Argenx • Others Discover detailed company profiles, pipeline strategies, licensing activities, and competitive benchmarking in DelveInsight's Polymyositis Market Report: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Polymyositis Marketed Therapies No therapies are currently approved specifically to treat Polymyositis. Existing management focuses on symptom control and immune suppression: • Corticosteroids - High-dose corticosteroids remain the cornerstone of first-line therapy. • Steroid-Sparing Immunosuppressants - Methotrexate, azathioprine, mycophenolate mofetil, and tacrolimus are used for long-term disease control. • IVIG and Rituximab - Reserved for refractory or severe cases. • Supportive Care - Physical rehabilitation, occupational therapy, nutritional support, and monitoring for complications such as interstitial lung disease and cardiac involvement. Polymyositis Emerging Therapies Anifrolumab (SAPHNELO) AstraZeneca / BMS A fully human monoclonal antibody that blocks the type I interferon receptor subunit 1 (IFNAR1), inhibiting interferon-driven autoimmune inflammation. It holds Orphan Drug Designation from the FDA and is in Phase III (JASMINE) as an add-on to standard of care, with data anticipated in 2027. Dazukibart (PF-06823859) - Pfizer A first-in-class humanized monoclonal antibody that selectively neutralizes interferon-beta (IFN-β), a key cytokine implicated in IIM inflammation. It is in a Phase III, multicenter, randomized, placebo-controlled trial, and holds Orphan Drug and Fast Track Designations (FDA) plus PRIME Designation (EMA). Efgartigimod - Argenx An FcRn antagonist that accelerates degradation of pathogenic IgG autoantibodies. It is in Phase III development for Polymyositis, with a data readout anticipated in Q3 2026. Polymyositis Market Drivers • Advancements in targeted biologic therapies addressing key immune pathways. • Rising diagnosis and improved disease recognition through better diagnostic tools (myositis-specific antibody testing, muscle MRI, electromyography). • Favorable regulatory support, including orphan drug incentives and expedited pathways. • Growing clinical pipeline of precision immunotherapies moving through Phase III trials. • Potential to reduce reliance on long-term corticosteroids through mechanism-based treatment. Polymyositis Market Barriers • No approved disease-specific therapies currently available. • Continued dependence on corticosteroids and broad immunosuppression. • Rarity of the disease limits large-scale clinical trial evidence. • Complex management of extra-muscular manifestations such as interstitial lung disease. • Diagnosis remains one of exclusion, with variability across healthcare systems. Request a sample PDF and evaluate Polymyositis market insights: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Scope of the Polymyositis Market Report • Study Period: 2022-2036 • Forecast Period: 2026-2036 • Base Year: 2026 • Coverage: 7MM (United States, EU4 Germany, France, Italy, and Spain, the United Kingdom, and Japan) • Key Polymyositis Companies: AstraZeneca, Pfizer, Argenx, and others • Therapeutic Assessment: Current standard-of-care immunosuppressive therapies and emerging Phase III pipeline biologics • Market Dynamics: Market drivers, barriers, opportunities, and future trends • Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Market Entry Strategies, KOL Views, Analyst Views, and Reimbursement Analysis • Additional Coverage: Epidemiology, Patient Population, Drug Uptake, Clinical Trials, Market Access, and Unmet Needs Discover the latest Polymyositis Market Opportunity: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: [email protected] City: Albany State: New York Country: United States Website: https://www.delveinsight.com/ About DelveInsight DelveInsight is a leading Business Consulting and Market Research firm focused exclusively on the life sciences industry. The company provides comprehensive market intelligence, competitive intelligence, epidemiology forecasting, pipeline assessment, pricing and reimbursement analysis, and healthcare consulting services that help pharmaceutical, biotechnology, and medical device companies accelerate strategic decision-making and commercial success. This release was published on openPR. Permanent link to this press release: Copy Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release. You can edit or delete your press release Polymyositis Market Expected to Gain Momentum Through 2036, According to DelveInsight here News-ID: 4624489 • Views: … 09-08-2026 | Health & Medicine Delveinsight Business Research LLP US Healthcare Market Poised for Continued Growth as It Anchors 26.29% of the Glo … DelveInsight's "US Healthcare Outlook Report, 2025" offers comprehensive insights into the healthcare scenario, regulatory policies, and reimbursement landscape in the United States. The report identifies key trends shaping the US healthcare market and provides insights into the country's demographic profile and healthcare infrastructure, along with a detailed look at the trends and segmentation of the US pharmaceutical and medical devices markets. To know more about the US Healthcare Outlook, market access … 09-08-2026 | Health & Medicine Delveinsight Business Research LLP Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market … DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - Market Insights, Epidemiology, and Market Forecast - 2036" report offers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. To know in detail about the PH-ILD market outlook, drug uptake, treatment scenario, and epidemiology trends, click here:https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Some of the Key … 09-08-2026 | Health & Medicine DelveInsight Business Research LLP Hot Flashes Clinical Trial Drug Development Pipeline Expands with Contributions … DelveInsight's "Hot Flashes Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Hot Flashes pipeline landscape. It covers the Hot Flashes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hot Flashes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates … 09-08-2026 | Health & Medicine DelveInsight Business Research LLP The Allergic Rhinitis Therapeutics Market Size in the 7MM was ~USD 10,400 millio … DelveInsight's "Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Discover Key Insights into the Allergic Rhinitis Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Allergic Rhinitis Market Report • In August 2026, Polyrizon finalized … All 5 Releases 08-31-2026 | Health & Medicine Delveinsight Business Research LLP Polymyositis Market Expected to Gain Momentum Through 2036 DelveInsight's Polymyositis Market Insights, Epidemiology, and Market Forecast 2036 report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology, as well as Polymyositis market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Get a detailed understanding of the evolving Polymyositis treatment landscape: https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr Key Facts of the Polymyositis Market Report • The Polymyositis market size was ~USD 120 million across the 7MM in 2025, … 08-25-2026 | Health & Medicine The Business Research Company Polymyositis Market Report Examines Leading Companies And Growth Opportunities The polymyositis market is poised for substantial expansion as advancements in targeted therapies and diagnostic technologies continue to evolve. With a growing emphasis on personalized medicine and autoimmune disease research, this sector is set to witness notable progress in the upcoming years. Let's delve into the market size, key players, emerging trends, and segmentation details shaping the polymyositis industry. Polymyositis Market Size and Projected Growth Through 2030 The polymyositis market … 12-11-2025 | Health & Medicine Exactitude Consultancy Polymyositis Market Treatment Advances and Growing Diagnosis Rates Overview The Polymyositis Market focuses on the growing demand for effective therapies to manage this rare inflammatory myopathy, which primarily affects skeletal muscles and leads to progressive weakness. The market is witnessing steady growth due to increasing awareness, advancements in diagnostic techniques, and the introduction of novel therapeutics. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70986 Market Size & Growth: • The global Polymyositis market is projected to reach USD X million by … 08-20-2025 | Health & Medicine Exactitude Consultancy Polymyositis Market Outlook 2025-2034: Trends, Growth, and Forecast Analysis Polymyositis (PM) is a rare, chronic autoimmune disease that causes muscle weakness and inflammation. It affects the muscles responsible for movement, leading to significant disability and a reduction in quality of life. As the understanding of autoimmune diseases expands and new therapeutic options emerge, the polymyositis market is experiencing significant growth. This article explores the key drivers, market trends, challenges, and growth opportunities in the polymyositis market, projected to expand … 11-28-2024 | Health & Medicine DelveInsight Business Research LLP Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated) DelveInsight's, "Polymyositis Pipeline Insight 2024" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Polymyositis Research. Learn more about our innovative pipeline … 09-24-2024 | Business, Economy, Finances, B … Verified Market Research Polymyositis Treatment Market Size Research Report 2024 𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Polymyositis Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in …